Invasive aspergillosis in glucocorticoid-treated patients

Medical Mycology

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Lewis, Russell E ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Aspergillosis; Corticosteroids; Immunity; Inflammation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ECHINOCANDIN; GALACTOMANNAN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; METHYLPREDNISOLONE; POSACONAZOLE; PREDNISONE; REACTIVE OXYGEN INTERMEDIATE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOINVASION; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FUMIGATUS; ASTHMA; AUTOPSY; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLLAGEN DISEASE; COLLAGEN VASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; FUNGAL INVASION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC THROMBOSIS; HISTOPATHOLOGY; HOST SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INVASIVE ASPERGILLOSIS; LOW DRUG DOSE; LUNG ASPERGILLOSIS; LUNG LAVAGE; MORTALITY; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PREVALENCE; RISK FACTOR; RISK REDUCTION; SPECIES INVASION; THROMBOSIS; IMMUNE DEFICIENCY; ISOLATION AND PURIFICATION; PATHOLOGY; REVIEW;

ANIMALIA; ASPERGILLUS;

ASPERGILLOSIS; ASPERGILLUS; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS;

EID: 67651109157     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802227159     Document Type: Article

References (85)

1. Fiedler U, Augustin HG. Angiopoietins: A link between angiogenesis and inflammation. Trends Immunol 2006; 27: 552-558.
2. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723.
3. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828-1838.
4. Rubin RH, Ikonen T, Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: The linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999; 1: 29-39.
5. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
6. Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494-503.
7. Berenguer J, Allende MC, Lee JW, et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression. Am J Respir Crit Care Med 1995; 152: 1079-1086.
8. Duncan MD, Wilkes DS. Transplant-related immunosuppression: A review of immunosuppression and pulmonary infections. Proc Am Thorac Soc 2005; 2: 449-455.
9. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982; 69: 617-631.
10. Hohl TM, Feldmesser M. Aspergillus fumigatus: Principles of pathogenesis and host defense. Eukaryot Cell 2007; 6: 1953-1963.
11. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 11-23.
12. Schaffner A. Therapeutic concentrations of glucocorticoids suppress the antimicrobial activity of human macrophages without impairing their responsiveness to gamma interferon. J Clin Invest 1985; 76: 1755-1764.
13. Bellocchio S, Moretti S, Perruccio K, et al. TLRs govern neutrophil activity in aspergillosis. J Immunol 2004; 173: 7406-7415.
14. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 2001; 7: 1291-1297.
15. Nathan C. Neutrophils and immunity: Challenges and opportunities. Nat Rev Immunol 2006; 6: 173-182.
16. Maneechotesuwan K, Essilfie-Quaye S, Kharitonov SA, Adcock IM, Barnes PJ. Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils. Chest 2007; 132: 98-105.
17. Tsuda Y, Takahashi H, Kobayashi M, et al. Three different neutrophil subsets exhibited in mice with different susceptibilities to infection by methicillin-resistant Staphylococcus aureus. Immunity 2004; 21: 215-226.
18. Lewis RE, Wiederhold NP, Chi J, et al. Detection of gliotoxin in experimental and human aspergillosis. Infect Immun 2005; 73: 635-637.
19. Gardiner DM, Waring P, Howlett BJ. The epipolythiodioxopiperazine (ETP) class of fungal toxins: Distribution, mode of action, functions and biosynthesis. Microbiology 2005; 151: 1021-1032.
20. Orciuolo E, Stanzani M, Canestraro M, et al. Effects of Aspergillus fumigatus gliotoxin and methylprednisolone on human neutrophils: Implications for the pathogenesis of invasive aspergillosis. J Leukoc Biol 2007; 82: 839-848.
21. Stanzani M, Orciuolo E, Lewis R, et al. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxinmediated apoptosis of monocytes. Blood 2005; 105: 2258-2265.
22. Spikes S, Xu R, Nguyen CK, et al. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis 2008; 197: 479-486.
23. Kupfahl C, Heinekamp T, Geginat G, et al. Deletion of the gliP gene of Aspergillus fumigatus results in loss of gliotoxin production but has no effect on virulence of the fungus in a low-dose mouse infection model. Mol Microbiol 2006; 62: 292-302.
24. Bok JW, Chung D, Balajee SA, et al. GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence. Infect Immun 2006; 74: 6761-6768.
25. Bellocchio S, Gaziano R, Bozza S, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005; 55: 214-222.
26. Lewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrob Agents Chemother 2007; 51: 1078-1081.
27. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91: 986-989.
28. Kojima R, Kami M, Nannya Y, et al. Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biol Blood Marrow Transplan 2004; 10: 645-652.
29. Stergiopoulou T, Meletiadis J, Roilides E, et al. Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol 2007; 127: 349-355.
30. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: Outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-540.
31. Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 2928-2936.
32. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplan 2002; 29: 15-19.
33. O'Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12 : 827-834.
34. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
35. Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322-330.
36. Jantunen E, Ruutu P, Niskanen L, et al. Incidence and risk factors for invasive fungal infections in allogenic BMT recipients. Bone Marrow Transplan 1997; 19: 801-808.
37. Wajszczuk CP, Dummer JS, HoM, et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347-353.
38. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999; 1: 229-236.
39. Gustafson TL, Schaffner W, Lavely GB, et al. Invasive aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy. J Infect Dis 1983; 148: 230-238.
40. Lortholary O, Ascioglu S, Moreau P, et al. Invasive aspergillosis as an opportunistic infection in nonallografted patients with multiple myeloma: A European organization for research and treatment of cancer. Clin Infect Dis 2000; 30: 41-46.
41. Khoo SH, Denning DW. Invasive aspergillosis in patients with AIDS. Clin Inf Dis 1994; 19 (Suppl. 1): S41-S48.
42. Leav BA, Fanburg B, Hadley S. Invasive pulmonary aspergillosis associated with high-dose inhaled fluticasone. N Engl J Med 2000; 343: 586.
43. Peter E, Bakri F, Ball DM, Cheney RT, Segal BH. Invasive pulmonary filamentous fungal infection in a patient receiving inhaled corticosteroid therapy. Clin Infect Dis 2002; 35: E54-E56.
44. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: A 20-year retrospective series. Hum Pathol 2002; 33: 116-124.
45. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259.
46. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
47. Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin Infect Dis 2007; 44: 373-379.
48. Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 506-511.
49. Torres HA, Chemaly RF, Storey R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006; 25: 382-388.
50. Torres HA, Reddy BT, Raad, II, et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002; 81: 388-397.
51. Jacobson K, Garcia R, Libshitz H, et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis 1998; 17: 615-621.
52. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am JMed 1996; 100: 171-178.
53. Shibuya K, Ando T, Hasegawa C, et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother 2004; 10: 138-145.
54. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357.
55. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177: 27-34.
56. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42: 5517-5522.
57. Cleary JD, Chapman SW, Nolan RL. Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells. Antimicrob Agents Chemother 1992; 36: 977-981.
58. Wilson E, Thorson L, Speert DP. Enhancement of macrophage superoxide anion production by amphotericin B. Antimicrob Agents Chemother 1991; 35: 796-800.
59. Wolf JE, Stein SH, Little KD, Abegg AL, Little JR. Amphotericin B selectively stimulates macrophages from high responder mouse strains. Immunopharmacol Immunotoxicol 1991; 13: 221-235.
60. Stein SH, Little JR, Little KD. Parallel inheritance of tissue catalase activity and immunostimulatory action of amphotericin B in inbred mouse strains. Cell Immunol 1987; 105: 99-109.
61. Sau K, Mambula SS, Latz E, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 2003; 278: 37561-37568.
62. Bellocchio S, Bozza S, Montagnoli C, et al. Immunity to Aspergillus fumigatus: The basis for immunotherapy and vaccination. Med Mycol 2005; 43 (Suppl. 1): S181-188.
63. Arning M, Kliche KO, Heer-Sonderhoff AH, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995; 38: 459-465.
64. Simitsopoulou M, Roilides E, Dotis J, et al. Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob Agents Chemother 2005; 49: 1397-1403.
65. Gil-Lamaignere C, Roilides E, Maloukou A, et al. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum. J Antimicrob Chemother 2002; 50: 1027-1030.
66. Simitsopoulou M, Roilides E, Maloukou A, Gil-Lamaignere C, Walsh TJ. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses 2008; 51: 147-154.
67. Roilides E, Lyman CA, Filioti J, et al. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46: 1974-1976.
68. Eierman DF, Yagami M, Erme SM, et al. Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia. Proc Natl Acad Sci USA 1995; 92 2815-2819.
69. Eierman DF, Yagami M, Erme SM, et al. Synergistic prevention of endotoxin induced mortality in rats by PGE1 and particles. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 341-343.
70. Simitsopoulou M, Roilides E, Likartsis C, et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus. Antimicrob Agents Chemother 2007; 51: 1048-1054.
71. Natarajan U, Brummer E, Stevens DA. Effect of granulocyte colony-stimulating factor on the candidacidal activity of poly polymorphonuclear neutrophils and their collaboration with fluconazole. Antimicrob Agents Chemother 1997; 41: 1575-1578.
72. Gujral S, Brummer E, Stevens DA. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans. J Inf Dis 1996; [n 174 n]: 888-890.
73. McElhaney-Feser GE, Raulli RE, Cihlar RL. Synergy of nitric oxide and azoles against Candida species in vitro. Antimicrob Agents Chemother 1998; [n 42 n]: 2342-2346.
74. Helmick RA, Fletcher AE, Gardner AM, et al. Imidazole antibiotics inhibit the nitric oxide dioxygenase function of microbial flavohemoglobin. Antimicrob Agents Chemother 2005; 49: 1837-1843.
75. Latge JP, Mouyna I, Tekaia F, et al. Specific molecular features in the organization and biosynthesis of the cell wall of Aspergillus fumigatus. Med Mycol 2005; [n 43 n] (Suppl. 1): S15-22.
76. Kahn JN, Hsu MJ, Racine F, Giacobbe R, Motyl M. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50: 2214-2216.
77. Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38: 1480-1489.
78. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: Pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12-23.
79. Abruzzo GK, Flattery AM, Gill CJ, et al. Evaluation of the echincocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41: 2333-2338.
80. Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-1471.
81. Chiller T, Farrokhshad K, Brummer E, Stevens DA. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001; 39: 99-103.
82. Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2: E35.
83. Brown GD. Dectin-1: A signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006; 6: 33-43.
84. Hohl TM, Van Epps HL, Rivera A, et al. Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display. PLoS Pathog 2005; 1: E30.
85. Lamaris GA, Lewis RE, Chamilos G, et al. Caspofunginmediated b-Glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and Non-Aspergillus molds. J Inf Dis 2008; [Epub ahead of print].